Proteomics characterization of triple-negative apocrine carcinoma reveals molecular features of progression and chemotherapy response

Triple-negative apocrine carcinoma (TNAC) is a rare and chemotherapy-insensitive subtype of triple-negative breast cancer (TNBC), characterized by specific morphology and molecular features. Despite limited chemotherapy response, TNAC shows favorable long-term survival, suggesting distinct resistance mechanisms. In this study, we present the first proteomics-based profiling of TNAC formalin-fixed paraffin-embedded (FFPE) samples using mass spectrometry. Our analysis reveals progressive activation of PI3K/AKT and androgen receptor (AR) signaling, along with upregulation of GTPase-related proteins, suggesting enhanced invasiveness. Post-chemotherapy TNAC displays increased inflammation and mixed ribosomal regulation, pointing to a metabolic shift in survival strategy. These findings support the rationale for exploring chemotherapy de-escalation strategies in TNAC, and highlight the potential utility of PI3K/AKT inhibitors and AR antagonists, possibly in combination with GTPase inhibitors, metabolic disruptors, or immunotherapy.

• Publication year

  2025

• Venue

  Scientific Reports

• Publication date

  2025-11-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41598-025-23449-2PMID 41233438PMCID 12615654
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy.

  2025cited by this paper
• Ki-67 Levels and Their Association With Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Prospective Observational Study

  2025cited by this paper
• Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022

  2024cited by this paper
• Neoadjuvant Chemotherapy in Breast Cancer: Evaluation of the Impact on Surgical Outcomes and Prognosis

  2024cited by this paper
• PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer

  2024cited by this paper
• Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma

  2024cited by this paper
• Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)

  2024cited by this paper
• New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer—Current State and Molecular Pathology Perspective

  2024cited by this paper
• Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review

  2023cited by this paper
• Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models

  2023cited by this paper
• Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer

  2023influential reference
• Rare subtypes of triple negative breast cancer: Current understanding and future directions

  2023cited by this paper
• Immunotherapy in breast cancer: an overview of current strategies and perspectives

  2023cited by this paper
• Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior.

  2023cited by this paper
• Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment

  2023cited by this paper
• The emerging role of mass spectrometry-based proteomics in drug discovery

  2022cited by this paper
• Androgen receptor function and targeted therapeutics across breast cancer subtypes

  2022cited by this paper
• Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors

  2022cited by this paper
• Targeting HER2-positive breast cancer: advances and future directions

  2022cited by this paper
• Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

  2022cited by this paper
• Second generation androgen receptor antagonists and challenges in prostate cancer treatment

  2022influential reference
• Triple-Negative Apocrine Breast Carcinoma Has Better Prognosis despite Poor Response to Neoadjuvant Chemotherapy

  2022cited by this paper
• PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

  2021cited by this paper
• 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

  2021cited by this paper
• Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer

  2021cited by this paper
• Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients

  2021cited by this paper
• 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.

  2021cited by this paper
• Frequency and spectrum of PIK3CA somatic mutations in breast cancer

  2020cited by this paper
• The 2019 World Health Organization classification of tumours of the breast

  2020cited by this paper
• Pembrolizumab for Early Triple-Negative Breast Cancer.

  2020cited by this paper
• Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity.

  2020cited by this paper
• Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas

  2020cited by this paper
• Triple-negative breast cancer incidence in the United States: ecological correlations with area-level sociodemographics, healthcare, and health behaviors

  2020cited by this paper
• Triple‐negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple‐negative breast cancers

  2020cited by this paper
• ARe we there yet? Understanding androgen receptor signaling in breast cancer

  2020cited by this paper
• Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy

  2019cited by this paper
• Prognosis in triple‐negative apocrine carcinomas of the breast: A population‐based study

  2019influential reference
• Toward understanding the origin and evolution of cellular organisms

  2019cited by this paper
• Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology

  2019cited by this paper
• Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer

  2018cited by this paper
• An inhibitor of oxidative phosphorylation exploits cancer vulnerability

  2018cited by this paper
• Long-Term Complete Response of an Androgen Receptor-Positive Triple-Negative Metastatic Breast Cancer to Abiraterone Acetate.

  2018cited by this paper
• Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

  2018cited by this paper
• Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.

  2018cited by this paper
• Genome-wide profiling of nardilysin target genes reveals its role in epigenetic regulation and cell cycle progression

  2017cited by this paper
• Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85α, androgen receptor, and Src.

  2016cited by this paper
• Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor–Positive Subset of Triple-Negative Breast Cancers

  2016cited by this paper
• Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.

  2015cited by this paper
• Ki67—no evidence for its use in node-positive breast cancer

  2015cited by this paper
• Apocrine carcinoma of the breast: a comprehensive review.

  2013cited by this paper
• Immunohistochemically defined subtypes and outcome of apocrine breast cancer.

  2013cited by this paper
• Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.

  2012cited by this paper
• Nardilysin and ADAM proteases promote gastric cancer cell growth by activating intrinsic cytokine signalling via enhanced ectodomain shedding of TNF-α

  2012cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• Chemotherapy for breast cancer (Review).

  2010cited by this paper
• Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

  2009cited by this paper
• Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.

  2008cited by this paper
• Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer.

  2007cited by this paper
• Induction of Androgen Receptor Expression by Phosphatidylinositol 3-Kinase/Akt Downstream Substrate, FOXO3a, and Their Roles in Apoptosis of LNCaP Prostate Cancer Cells*

  2005cited by this paper
• Androgen Receptor Mediates Non-genomic Activation of Phosphatidylinositol 3-OH Kinase in Androgen-sensitive Epithelial Cells*

  2004cited by this paper
• Activation of Phosphatidylinositol 3-Kinase/Akt Pathway by Androgen through Interaction of p85α, Androgen Receptor, and Src*

  2003cited by this paper
• KEGG: Kyoto Encyclopedia of Genes and Genomes

  2000cited by this paper
• KEGG: Kyoto Encyclopedia of Genes and Genomes

  1999influential reference

• No citing papers are available for this paper.